DePuy Orthopaedics Newswire

DePuy Orthopaedics Newswire

Comprehensive Real-Time News Feed for DePuy Orthopaedics.

Results 1 - 20 of 526 in DePuy Orthopaedics

  1. EXCLUSIVE - "Carson: - Problematic' Donors Fill Debate AudienceRead the original story w/Photo

    15 hrs ago | Breitbart.com

    GOP presidential candidate Dr. Ben Carson told Breitbart News that it is "problematic" if establishment donors and special interests fill the audience at GOP debates, as GOP frontrunner Donald Trump suggested during the Saturday debate, and again during his Sunday campaign rally. "Do I recognize that we have big money involved in just about everything that has to do with politics? Absolutely.

    Comment?

  2. Use General Dynamics' Recovery Rally to Bail Out of Longs: Real Money's Bruce KamichRead the original story

    18 hrs ago | TheStreet.com

    In the chart of General Dynamics, above, you can see that prices started down in earnest in December. Prices broke key support at $135 in January and now returned to the scene of the crime.

    Comment?

  3. EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12Read the original story w/Photo

    Friday Feb 5 | GlobeNewswire

    EPIRUS Biopharmaceuticals, Inc. , a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies , today announced it will participate in multiple panel discussions at the 4th Annual Bloomberg Intelligence Healthcare Event on Friday, Feb. 12. The panels will begin at 1:30 pm ET and focus on the evolving strategies for biosimilars, as well as provide legal and regulatory updates on biosimilars. The conference will be held on Friday, Feb. 12 starting at 8:30 am ET in New York City.

    Comment?

  4. 2 firms teaming to battle diabetesRead the original story w/Photo

    Friday Feb 5 | Arkansas Online

    Johnson & Johnson, continuing its quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem-cell treatment that could fix the life-threatening hormonal disorder.

    Comment?

  5. Which Medical Device Firm Should You Work For?Read the original story w/Photo

    Thursday Feb 4 | Medical Device/Diagnostic Ind.

    Johnson & Johnson just announced that it will let go 4%-6% of its device workforce - which most likely includes medical sales positions - but the diversified conglomerate still comes out as a winner when it comes to best medical device firms to work in medical sales. The 5th annual survey from MedReps brought responses from more than 1,400 responses and they overwhelmingly chose Johnson & Johnson, Medtronic and Stryker as the best places to work for in medical sales.

    Comment?

  6. Possible cure for diabetes?Read the original story w/Photo

    Thursday Feb 4 | CKNW News Talk 980

    They're hesitant to use the word cure, but researchers in Baltimore may have come up with "potentially the real deal" in their search for a cure for type 1 diabetes. Two American companies, Johnson and Johnson and ViaCyte are joining forces to speed development of the first stem cell treatment that could fix the disorder.

    Comment?

  7. Johnson & Johnson - due for a shake?Read the original story w/Photo

    Thursday Feb 4 | Financial Times

    Feb 4, 2016 : Johnson & Johnson is hunting for potential acquisitions as it seeks to spend $18bn of cash. Perhaps healthcare activists should turn their guns to Switzerland, says Lex's Rob Armstrong, instead of focusing on the US-based pharma group.

    Comment?

  8. Recent Research Analysts' Ratings Changes for Johnson & JohnsonRead the original story w/Photo

    Thursday Feb 4 | Daily Political

    They now have a $120.00 price target on the stock, up previously from $115.00. 1/27/2016 - Johnson & Johnson was given a new $108.00 price target on by analysts at Independent Research GmbH.

    Comment?

  9. Medical devices consolidation continuesRead the original story

    Thursday Feb 4 | Chemistry World

    Healthcare major Abbott has agreed to buy US medical diagnostics specialist Alere for $5.8 billion , taking control of Alere's $2.6 billion in debt. The deal strengthens Abbott's position in point-of-care diagnostics - tests designed to be run in hospitals, doctors' surgeries or even at home - to support increasingly targeted treatments.

    Comment?

  10. Just Published: 'Thermoplastic Vulcanizates (TPV) Market 2015-2019'Read the original story w/Photo

    Wednesday Feb 3 | PR-inside.com

    Technavio's market research analyst predicts the thermoplastic vulcanizates market to grow at a rate of around 7% during the forecast period. The rising adoption of TPV as a replacement for PVC in the healthcare sector is the primary driver for the growth of this market.

    Comment?

  11. Israel Pic: Full Moon over Har Hotzvim JerusalemRead the original story w/Photo

    Thursday Jan 14 | Mystical Paths

    Israel is an incredible land, the Holy Land. Whether it's natural views changing from beach to desert to lake to mountains, or holy places, or ancient ruins, or modern technology parks, every bit of Israel presents stunning views.

    Comment?

  12. Investor pressures J&J to consider split up: sourcesRead the original story

    Wednesday Jan 27 | WNFL-AM Green Bay

    Artisan Partners, a major shareholder in Johnson & Johnson, has urged several activists to pressure the consumer products giant to consider major changes that include a potential split, according to sources and documents. Artisan has asked Johnson & Johnson's management to consider separating its three divisions - consumer products, pharmaceuticals and medical devices - into standalone companies in hopes of unlocking up to $90 billion in enterprise value, said sources familiar with the matter.

    Comment?

  13. Investor pressures J&J to consider split up: sourcesRead the original story w/Photo

    Wednesday Jan 27 | Silicon Alley Insider

    Artisan Partners, a major shareholder in Johnson & Johnson, has urged several activists to pressure the consumer products giant to consider major changes that include a potential split, according to sources and documents. Artisan has asked Johnson & Johnson's management to consider separating its three divisions - consumer products, pharmaceuticals and medical devices - into standalone companies in hopes of unlocking up to $90 billion in enterprise value, said sources familiar with the matter.

    Comment?

  14. Dairy Queen taps Cineplex for in-store signageRead the original story w/Photo

    Wednesday Jan 27 | Marketing

    Dairy Queen has selected Cineplex Digital Media [CDM] to provide software its in-store merchandising network across Canada and the U.S. Cineplex will provide content management software for Dairy Queen and its franchisees to manage marketing content for digital menu boards. "Broadening our digital merchandising initiatives is a key strategic priority for us," said Janna Rider , director of digital merchandising for American Dairy Queen Corporation, in a statement.

    Comment?

  15. Is Direct-to-Consumer TV Advertising a Losing Proposition?Read the original story w/Photo

    Wednesday Jan 27 | Pharma Marketing Blog

    A few weeks ago I said "Forgettaboutit! The numbers are not yet in for 2015, but if it's anything like 2014 -- and judging by personal experience -- the drug industry will be spending even MORE money on TV DTC ads." The Top 10 TV DTC Rx advertisers spent $876.3 million in 2015 .

    Comment?

  16. Pharma "Cash Call" For New AntibioticsRead the original story

    Wednesday Jan 20 | BioSpace

    Pharma 'Cash Call' For New Antibiotics More than 80 pharmaceutical companies have called on governments to develop new ways of paying them to develop antibiotics. In a joint declaration, at the World Economic Forum, they said the value of antibiotics "does not reflect the benefits they bring to society".

    Comment?

  17. Johnson & Johnson 4Q Sales Drop 2.4 Percent, But U.S. Vision Care Sales GrowRead the original story w/Photo

    Tuesday Jan 26 | Vision Monday

    Johnson & Johnson announced sales of $17.8 billion for the fourth quarter of 2015, a decrease of 2.4 percent as compared to the fourth quarter of 2014. Operational sales results increased 4.4 percent and the negative impact of currency was 6.8 percent.

    Comment?

  18. But this was a good day to be a contrarian.Read the original story

    Tuesday Jan 26 | TheStreet.com

    After an ugly close yesterday, another big drop in China, further pressure on oil and weak actions in futures overnight, it looked like we may be heading for some trouble today. Instead, the contrarians had a great day.

    Comment?

  19. Johnson & Johnson: Like ClockworkRead the original story w/Photo

    Tuesday Jan 26 | Seeking Alpha

    I have covered the power of the dividend from JNJ long-term and feel it is one of the most reliable stocks you can own. Currency is an issue but the company is pumping money into R&D and making moves allowing it to grow earnings at a strong clip.

    Comment?

  20. Steady Growth Supports J&J's Wide MoatRead the original story

    Tuesday Jan 26 | Morningstar

    Johnson & Johnson reported strong fourth-quarter results slightly ahead of our expectations and issued 2016 guidance above our projections, but we don't expect any major changes to our $102 fair value estimate based on the minor outperformance. Steady growth across consumer, devices and drugs reinforces our wide moat rating, and returns on invested capital are well positioned to exceed the cost of capital over the long term.

    Comment?